At the beginning of H2, we announced the appointment of Maria Soler Nunez as Head of Group Operations.
We announced a CHF ~500 million investment to build a large-scale commercial drug product facility in Stein (CH).
We also announced a solid financial performance at Half-Year 2022 with 16.8% CER sales growth and 33.1% CORE EBITDA margin.
We announced our collaboration with Touchlight to expand our end-to-end offering for mRNA manufacturing.
We completed the expansion of our Highly Potent API (HPAPI) multipurpose suite for payload-linkers in Visp (CH).
We also announced the appointment of Daniel Palmacci as President of the Cell & Gene division.